newsfilter
← Latest News
Business Wire·

VBI Vaccines Reports Full Year 2022 Financial Results

Access to PreHevbrio [Hepatitis B Vaccine (Recombinant)] continues to broaden in the U.S. and beyond, with additional approvals received in 2022 in Europe and Canada Clinical data expected throughout 2023 from: (i)